Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM

Colorectal Cancer Clinical Trial

Official title:

Pre-and Post-operative Cetuximab Plus mFOLFOX6 Versus mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable Colorectal Liver Metastases

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05948072
• Other study ID #: NEO-HR-CRLM
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: July 15, 2023
• Est. completion date: July 15, 2026

Study information

• Verified date: July 2023
• Source: Fudan University
• Contact: Jianmin Xu, MD
• Phone: 86-021-64041990
• Email: xujmin[@]aliyun.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

For patients with initially resectable colorectal cancer liver metastases who have high-risk factors, neoadjuvant therapy is currently considered a consensus approach. However, there is ongoing debate regarding the optimal treatment strategy. Our study aims to investigate whether the addition of cetuximab to neoadjuvant chemotherapy improves outcomes compared to neoadjuvant chemotherapy alone. The objective of this phase III clinical trial is to determine whether the combination of cetuximab and mFOLFOX6 chemotherapy is superior to neoadjuvant mFOLFOX6 chemotherapy alone for patients with initially resectable colorectal cancer liver metastases who have wild-type RAS/BRAF and high-risk factors.

Description:

Primary • To determine whether the addition of cetuximab to neoadjuvant mFOLFOX6 chemotherapy results in improved event-free survival when compared with neoadjuvant mFOLFOX6 chemotherapy alone in patients with high-risk & RAS/BRAF-wild-type & resectable colorectal liver metastases. Secondary - To evaluate the overall survival of patients treated with these regimens. - To evaluate the quality of life of patients treated with these regimens. - To evaluate the preoperative remission rate, safety, surgical complications, actual resection rate, pathological resection status of patients treated with these regimens.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 250
• Est. completion date: July 15, 2026
• Est. primary completion date: July 15, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Histological proof of colorectal adenocarcinoma;

2. Age = 18 years and =75 years;

3. RAS wild type;

4. CRS=3;

5. Simultaneous liver-limited metastases;

6. At least one measurable liver metastases;

7. World Health Organization (WHO) performance status 0-1;

8. Life expectancy = 3 months;

9. Adequate hematologic function: absolute neutrophil count (ANC)=1.5×109/l, platelets=100×109/l, and hemoglobin(HB) = 9g/dl;

10. Adequate liver and renal function: total bilirubin =2.0 mg/dl, serum transaminases = 5x upper limit of normal(ULN), and serum creatinine = 1.5x ULN and creatinine clearance = 30 ml/min;

11. Written informed consent.

Exclusion Criteria:

1. Previous systemic treatment for metastatic disease;

2. Previous surgery for metastatic disease;

3. Extrahepatic metastases;

4. Unresectable primary tumor;

5. Major cardiovascular events (myocardial infarction, severe/unstable angina, congestive heart failure, CVA) within 12 months before randomisation;

6. Acute or subacute intestinal obstruction;

7. Second primary malignancy within the past 5 years;

8. Drug or alcohol abuse;

9. No legal capacity or limited legal capacity;

10. Pregnant or lactating women;

11. Uncontrolled hypertension, or unsatisfactory blood pressure control with =3 antihypertensive drugs;

12. Peripheral neuropathy;

Related Conditions & MeSH terms

• Colorectal Cancer
• Liver Metastases
• Neoplasm Metastasis

Intervention

Drug:
• mFOLFOX6 + Cetuximab
Cetuximab + mFOLFOX6: Cetuximab (500mg/m2 IV ) will be given. Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
• mFOLFOX 6
mFOLFOX6: Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.

Locations

Country	Name	City	State
China	Zhongshan hosptial, Fudan University	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Event-free survival	The Event-free survival (EFS) was defined as the period from the start of initial medication to the date of tumor relapse, progression, or death	3 years
Secondary	overall survival	The overall survival (OS) was defined as the period from the start of initial medication until death from any cause, at which point the data was censored.	5 years
Secondary	postoperative hospital stay	The postoperative hospital stay is defined as the number of date from the first day after operation to discharge.	30 days post operatively
Secondary	postoperative complication	Patients will be evaluated for surgical morbidity during 1 month. Postoperative morbidity will be scored according 'Clavien-Dindo Grade'.	After surgery during one month
Secondary	postoperative mortality	any death occured within 90 days after the last resection of primary and metastatic lesions	After surgery during 90 days